Active Biotech’ Tasquinimod Receives the US FDA’s Orphan Drug Designation for the Treatment of Myelofibrosis
- The US FDA has granted ODD to tasquinimod for the treatment of myelofibrosis. In preclinical models, the results showed a clear therapeutic potential of Tasquinimod as monothx. & in combination with standard multiple myeloma therapy
- The therapy is also being studied in an ongoing P-Ib/IIa study for r/r MM. Tasquinimod has been studied as an anti-cancer agent in patients with solid cancers including a P-III trial for metastatic prostate cancer
- Active Biotech & Erasmus MC have initiated a research collaboration for tasquinimod including preclinical studies & clinical PoC studies in patients with myelofibrosis. The study will be financed by Oncode and is expected to initiate in early 2023
Ref: Businesswire | Image: Active Biotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].